Author:
Lee Soon-Young,Cho Yeon-Kyoung,Bae Chun-Sik,Kim Gyeyeop,Lee Min-Jae,Cho Seung-Sik,Jeon In-Chul,Park Dae-Hun
Abstract
AbstractAge-related macular degeneration (AMD) is one of the leading causes of blindness. AMD is currently incurable; the best solution is to prevent its occurrence. To develop drugs for AMD, it is crucial to have a model system that mimics the symptoms and mechanisms in patients. It is most important to develop safer and more effective anti-AMD drug. In this study, the dose of A2E and the intensity of blue light were evaluated to establish an appropriate atrophic in vitro model of AMD and anti-AMD effect and therapeutic mechanism of Codonopsis lanceolata. The experimental groups included a control group an AMD group treated with A2E and blue light, a lutein group treated with 25 μM lutein after AMD induction, and three groups treated with different doses of C. lanceolata (10, 20, and 50 μg/mL) after AMD induction. Intrinsic apoptotic pathway (Bcl-2 family), anti-oxidative system (Keap1/Nrf2/HO-1 antioxidant response element), and anti-carbonyl effect (4-hydroxynonenal [4-HNE]) were evaluated using immunofluorescence, MTT, TUNEL, FACS, and western blotting analyses. A2E accumulation in the cytoplasm of ARPE-19 cells depending on the dose of A2E. Cell viability of ARPE-19 cells according to the dose of A2E and/or blue light intensity. The population of apoptotic or necrotic cells increased based on the A2E dose and blue light intensity. Codonopsis lanceolata dose-dependently prevented cell death which was induced by A2E and blue light. The antiapoptotic effect of that was caused by activating Keap1/Nrf2/HO-1 pathway, suppressing 4-HNE, and modulating Bcl-2 family proteins like increase of antiapoptotic proteins such as Bcl-2 and Bcl-XL and decrease of proapoptotic protein such as Bim. Based on these findings, 30 μM A2E and 20 mW/cm2 blue light on adult retinal pigment epithelium-19 cells was an appropriate condition for AMD model and C. lanceolata shows promise as an anti-AMD agent.
Funder
the National Research Foundation of Korea (NRF) grant funded by the Korea government
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Jonas, J. B. et al. Updates on the epidemiology of age-related macular degeneration. Asia-Pac J. Ophthalmol. 6, 493–497 (2017).
2. Wang, Y. et al. Global incidence, progression, and risk factors of age-related macular degeneration and projection of disease statistics in 30 years: A modeling study. Gerontol. 68, 721–735 (2022).
3. The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564–572 (2004).
4. World Health Organization, Ageing and health. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health. Accessed 26th Jan 2023 (2023).
5. Crouch, R. K., Koutalos, Y., Kono, M., Schey, K. & Ablonczy, Z. A2E and lipofuscin. Prog. Mol. Biol. Transl. Sci. 134, 449–463 (2015).